Key Developments: CTi Biopharma Corp (CTIC.O)

CTIC.O on Consolidated Issue listed on NASDAQ Capital Market

2.44USD
19 Dec 2014
Price Change (% chg)

$0.01 (+0.41%)
Prev Close
$2.43
Open
$2.36
Day's High
$2.51
Day's Low
$2.36
Volume
4,212,385
Avg. Vol
1,438,326
52-wk High
$4.25
52-wk Low
$1.83

Search Stocks

Latest Key Developments (Source: Significant Developments)

CTI BioPharma Corp presents data demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells
Tuesday, 9 Dec 2014 02:00am EST 

CTI BioPharma Corp:Announces data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development.Says preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays.Says about 30 pct of patients with AML have a mutation in FLT3, a known poor prognostic factor, and an important target for drug development.  Full Article

CTI BioPharma Corp prices underwritten public offering of $35 mln of convertible preferred stock
Friday, 7 Nov 2014 09:15am EST 

CTI BioPharma Corp:Prices underwritten public offering of 35,000 shares of Series 21 Preferred Stock, offered at a price to the public of $1,000 per share of Series 21 Preferred Stock.Each share of Series 21 Preferred Stock is convertible at the option of the holder, at any time, into 500 shares of common stock at a conversion price of $2.00 per share of common stock, for a total of 17.5 mln shares of common stock.Shares of Series 21 Preferred Stock will automatically convert into shares of common stock in certain circumstances.Shares of the Series 21 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock, but would be entitled to a liquidation preference over the common stock in certain liquidation events.Series 21 Preferred Stock will have no voting rights on general corporate matters.Gross proceeds to CTI from this Offering are expected to be $35 mln, before deducting underwriting discounts and commissions and other estimated offering expenses payable by CTI.Estimates that its net proceeds from the Offering after deducting commission and expenses and other estimated offering expenses payable by CTI will be about $32.8 mln.  Full Article

CTI BioPharma Corp announces proposed public offering of convertible preferred stock
Thursday, 6 Nov 2014 04:15pm EST 

CTI BioPharma Corp:Intends to offer and sell, subject to market and other conditions, shares of its Series 21 Preferred Stock in an underwritten public offering.Each share of Series 21 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance, into shares of common stock prior to the automatic conversion of such shares in certain circumstances.Shares of the Series 21 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock, but would be entitled to a liquidation preference over the common stock in certain liquidation events.Series 21 Preferred Stock will have no voting rights on general corporate matters.Plans to use the net proceeds to advance the commercialization of PIXUVRI (pixantrone), accelerate the pre-commercial activities for pacritinib, as well as for general corporate purposes, preclinical and clinical trials, the preparation and filing of new drug applications and general working capital.  Full Article

CTI BioPharma raises FY 2014 operating loss outlook
Wednesday, 29 Oct 2014 04:01pm EDT 

CTI BioPharma Corp:Revises FY 2014 non-GAAP operating loss to range from about $66 - $71 mln rather than $45 - $50 mln.Excludes non-cash share-based compensation expense.  Full Article

CTI BioPharma Corp acquires exclusive worldwide license to tosedostat
Monday, 27 Oct 2014 02:30am EDT 

CTI BioPharma Corp:Says that it has acquired worldwide rights to tosedostat through concurrent transactions with Vernalis R&D Limited (Vernalis), originator of tosedostat, and Chroma Therapeutics Ltd, through which CTI previously held sublicense with respect to tosedostat in North, Central and South America.Tosedostat is first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival.Under terms of asset purchase agreement with Chroma, CTI acquired all of Chroma's right, title and interest in tosedostat and certain related assets in exchange for issuing to Chroma $21.3 million in shares of CTI's preferred stock convertible into 9 million shares of CTI common stock.  Full Article

CTI BioPharma Corp and Servier announce exclusive license and collaboration agreement to develop and commercialize PIXUVRI
Wednesday, 17 Sep 2014 01:30am EDT 

CTI BioPharma Corp and Servier:Enter into exclusive license and collaboration agreement to develop and commercialize PIXUVRI(pixantrone) in transaction valued at up to 103.0 mln euros (about $133.5 million) if all milestones are achieved.Under agreement, CTI retains full commercialization rights for PIXUVRI in Austria, Denmark, Finland, Germany, Israel, Norway, Sweden, Turkey, the United Kingdom and the U.S., with Servier having exclusive rights to commercialize PIXUVRI in all other countries.  Full Article

CTI Biopharma Corp reaffirms FY 2014 operating loss outlook
Monday, 4 Aug 2014 04:01pm EDT 

CTI Biopharma Corp:Continues to expect FY 2014 non-GAAP operating loss will be about $45 to $50 million.It excludes non-cash share-based compensation expense.  Full Article

CITI BioPharma Corp announces United Kingdom National Cancer Research Institute AML Cooperative Group initiates randomized phase 2 trial evaluating tosedostat plus cytarabine for older patients
Thursday, 12 Jun 2014 01:30am EDT 

CTI BioPharma Corp:Says initiation of an international cooperative group Phase 2 clinical trial of tosedostat in combination with low-dose cytarabine in older patients with Acute Myeloid Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS).Tosedostat is a selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival.Trial is being conducted by National Cancer Research Institute Haematological Oncology Study Group under the sponsorship of Cardiff University.Trial management group is led by Professor Alan K. Burnett, Head of Haematology in the Department of Medical Genetics, Haematology and Pathology at the School of Medicine at Cardiff University.Chroma Therapeutics Ltd., from whom CTI licensed tosedostat, is facilitating drug supply for the trial.  Full Article

Cell Therapeutics announces change of name to CTI BioPharma Corp
Friday, 30 May 2014 01:30am EDT 

Cell Therapeutics Inc:Says that it will change its corporate name to CTI BioPharma Corp. effective May 30, 2014.Common stock will continue to trade under its current ticker symbol CTIC.  Full Article

Cell Therapeutics Inc reaffirms FY 2014 operating loss outlook
Tuesday, 29 Apr 2014 04:01pm EDT 

Cell Therapeutics Inc:Reaffirms FY 2014 non-GAAP operating loss to approximate $45 to $50 mln.  Full Article

BUZZ-U.S. Stocks on the Move-Haliburton, EMC Corp, CTI Biopharma

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for more market insights, including options activity, ; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks dipped at the open on Monday as developments in Ukraine and the Gaza Strip look to dominate trading amid a thin economic calendar. The Dow Jones industrial average was down 0.39 percent at 17,032.78, t

Search Stocks